



Development of novel formulations to enhance in vivo
transdermal permeation of tocopherol
Tocopherol represents a big challenge for transdermal per-
meation owing to its extreme hydrophobicity and large mo-
le cular mass. The aim of the present study was to develop 
alpha-tocopherol (T) topical formulations and evaluate 
their ex vivo and in vivo permeation. Franz diffusion cells 
were used for ex vivo permeation, and neonatal rats were 
used for in vivo permeation. Seven gel formulations and 21 
liquid formulations were investigated for physical stability, 
viscosity and permeation of T. Analysis of T was performed 
by a validated HPLC method using a UV detector. The ex 
vivo permeation from gel and emulsion formulations was 
very poor (0.001–0.015 %). Highest permeation was ob-
served from monophasic liquid formulations containing 
dimethyl sulfoxide (DMSO), tocopheryl polyethylene gly-
cols (TPGs), propylene glycol, ethanol and 9.5 % T. The in 
vivo results demonstrated higher retention in the epidermis 
compared to subcutaneous tissues, 1377 and 1.13 µg g–1, re-
spectively. Increasing T concentration from 4.8 to 9.5 % did 
not increase the amount permeated or % of T retained. It 
was concluded that simple solutions of T in the presence of 
DMSO and TPGs were more promising systems for effec-
tive transdermal permeation compared to gel, emulsion or 
oleaginous systems.
Keywords: tocopherol, topical formulation, chemical analy-
sis, ex vivo and in vivo, skin barrier
Human skin is the largest organ of the human body providing a natural protective 
barrier against penetration of toxic exogenous compounds/microbes and other environ-
mental stress factors. In addition, it prevents loss of water and essential compounds from 
the human body and also provides a promising site for administration of drugs for local 
and/or systemic therapy (1–3). Due to constant exposure of the skin to various environ-
mental factors, the skin is susceptible to oxidative stress, which occurs when the number 
of pro-oxidant species exceeds the number of antioxidant species (4, 5). a-Tocopherol (T) 
plays a very important role in protecting skin and other organs, since it is the most active 
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lipophilic antioxidant in biological membranes (6) and, together with ascorbic acid, consti-
tutes the »antioxidant network« that protects the skin against oxidative damage (7). T may 
be the most important antioxidant because it is present in limited quantities, humans can-
not synthesize it, it is readily depleted by UV radiation and other oxidative stresses such 
as ozone, and it is the dominant antioxidant responsible for protecting the stratum cor-
neum lipids from oxidation (5, 8). Moreover, T plays different roles in the maintenance of 
skin physiological conditions. It has a moisturizing effect by limiting trans-epidermal wa-
ter loss and seems to be able to regulate keratin turnover (9, 10). Therefore, T and its esters 
are among the best established ingredients in the over the counter (OTC) products for the 
delay/treatment of skin aging. However, results of activation of the prodrug T-acetate (TA) 
into the active form of T following topical administration are controversial and depend on 
the formulation factors and the skin model investigated (11).
Conventional means of applying drugs to the skin include vehicles such as ointments, 
creams, gels, and »passive« patch technology. Therefore, some dosage forms have been 
de veloped and/or modified to enhance the driving force of drug diffusion (thermodyna-
mic activity) and/or increase the permeability of the skin. Such approaches include the use 
of penetration enhancers (12), supersaturated systems (13), prodrugs or metabolic ap-
proach (14–16), microemulsions (3), liposomes and other vesicles (17–19). Transdermal de-
livery of T represents a big challenge, since it exhibits extremely high lipophilic properties 
with log P values of 9.3–13.4, as determined by calculation methods (20). Furthermore, 
permeation of T is particularly challenging because it is sparingly water-soluble and at the 
same time water is usually used as a major component of the receiver compartment (21).
In a previous work, we investigated some commercial cosmetic products containing 
T/TA. Results of in vivo permeation and hydrolysis of TA into T revealed that no conversion 
of acetate ester was observed in the neonatal rat skin model (22). Hence, it is not surprising 
that researchers are working in the direction of using the active form of vitamin (T) rather 
than the prodrug (TA), aiming at improving its stability and permeation by optimizing the 
formulation factors and application of innovative technologies (23–25).
Consequently, the main objectives of the present study were to develop and optimize 
novel T formulations and to study drug permeation from such formulations through the 
neonatal rat skin (ex vivo and in vivo).
EXPERIMENTAL
Chemicals
Methanol, propylene glycol, Tween 80, dimethyl sulfoxide (DMSO-Merck KGaA, Ger-
many); glycerol (Fisher Scientific UK Ltd, UK); isopropyl myristate 95 % (Fluka Chemie, 
Switzerland); polyethylene glycol 400, Carbomer 934, methylcellulose, Span 80 (Loba Che-
mie, India); carboxymethylcellulose – NaC5013(CMC-Na), hydroxypropyl methylcellulose 
(HPMC) (Sigma Chemical Co, USA); Eudragit RL100 (Rohn Pharma Polymers, Germany); 
alpha-tocopherol (Sigma Aldrich Chemie GmbH, Germany); dimethylformamide (DMF) 
(Riedel-de Haen Laborchemikalien, GmbH & Co. KG, Germany); D-a-tocopheryl polyeth-
ylene glycol 1000 – succinate (Courtesy of ISOCHEM S.A., France); purified water from 
Milli-Q synthesis, resistivity 18.2 MΏ cm at 25 °C (Millipore SAS, France).
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Analysis of alpha-tocopherol
The method involved a HPLC system with a variable wavelength and PDA detector 
(Waters 2690 Separations Module, USA), a disposable guard column C-18 and a RP Waters 
Symmetry C-18 column (26).
Alpha-tocopherol formulation studies
Gel formulations. – Seven gel formulations were prepared (GF1-GF7) using different 
gel-forming polymers (Methylcellulose, HPMC, Carbomer 934, Eudragit RL100, and CMC-
Na). Some additives were included, such as ethanol, PEG 400, isopropyl myristate (ISPM), 
in addition to water. Each formula contained about 5 % T and the composition of all for-
mulations is summarized in Table I. Viscosity was assessed for each formulation and those 
showing good physical stability, without any sign of T separation, were further tested for 
ex vivo skin permeation.
Liquid formulations. – Twenty-one formulations (F1-F21) containing T (5–10 %, V/V) in 
the form of emulsions (F1-F6) or solutions in various solvents or mixtures thereof (F7-F21) 
were prepared and tested for physical stability and skin permeation. Selected semi-polar 
and/or polar solvents/enhancers such as ethanol, DMF, DMSO, propylene glycol, PEG 400 
and TPGs, in addition to Tween 80 and Span 80 as surfactants were used (Table II). The 
method of emulsion preparation was simple trituration of aqueous and oily phases, and 
other solution formulations were made by simple mixing of T with other ingredients. All 
experiments were carried out in containers protected from light by aluminum foils and in 
dimmed room. Formulations showing good physical stability were further tested for skin 
Table I. Composition and viscosity of gel formulations (GF1-GF7)
Ingredients/viscosity GF1 GF2 GF3 GF4 GF5 GF6 GF7
Alpha-tocopherol 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g
NaCMC 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g 0 0
Eudragit RL100 0 0 0 0 0 5 5
Carbomer 934 0.016 g 0 0 0 0 0 0
Water 3.0 mL 3.0 mL 3.0 mL 3.0 mL 3.0 mL 0 0
Ethanol 4.0 mL 4.0 mL 4.0 mL 4.0 mL 4.0 mL 7.0 mL 5.0 mL
PEG 400 3.0 mL 3.0 mL 2.0 mL 1.0 mL 0 3.0 mL 5.0 mL
Isopropyl myristate 0 0 1.0 mL 2.0 mL 3.0 mL 0 0
Viscosity, mPa s a b 279.11 a a 72.3 79.54
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F1c 1 3 0.1 0.4 2.5 0 0 0 0 0 8.68 0.01527 (0.001407)
F2c 1 2.5 0.1 0.4 2.5 0 0 0 0 0 8.01 0.0123 (0.003211)
F3c 1 3 0.2 0.8 2.5 0 0 0 0 0 9.56 0.008503 (0.002714)
F4c 1 2.5 0.2 0.8 2.5 0 0 0 0 0 9.16 0.0141 (0.001386)
F5b 1 2 0.1 0.4 2.5 1 0 0 0 0 8.25 b
F6c 1 2 0.1 0.4 2.5 0 1 0 0 0 7.95 0.0064 (0.014658)
F7c 1 0 0 0 1.5 0 1.5 0 6 0 24.96 0.008628 (0.003117)
F8c 1 0 0 0 2.5 0 1.5 5 0 0 22.35 0.026798 (0.001052)
F9c 1 0 0 0 2.5 0 3 5 0 0 22.03 0.017485 (0.002979)
F10c 1 0 0 0 2.5 0 5 5 0 0 21.2 0.028933 (0.001487)
F11b 1.35 0 0 0 2.5 0 5 5 0 0 22.04 b
F12 1 0 0 0 2.5 0 5 1.5 0 0.5 21.24 0.050823 (0.005798)
F13 1 0 0 0 2.5 0 5 0 1.5 0.5 19.02 0.016073 (0.007694)
F14a 1 0 0 0 0 0 3.5 0 5.0 0.5 a a
F15 0 0 0 0 2.5 0 5 1.5 0 0.5 19.11 0
F16 1 0 0 0 2.5 0 5 1.5 0 1.0 21.52 0.03857 (0.013567)
F17 1 0 0 0 2.5 0 5 1.5 0 1.5 21.07 0.049129 (0.014958)
F18 1 0 0 0 2.5 0 5 1.5 0 0.25 19.86 0.051059 0.012194
F19 0.5 0 0 0 2.5 0 5 1.5 0 0.5 20.22 0.149667 (0.001452)
F20 1 0 0 0 2.5 0 4.5 1.5 0 0.5 20.15 0.032041 (0.002331)
F21 1 0 0 0 2.0 0 4.5 2.0 0 0.5 22.54 0.022176 (0.010471)
a Phase separation shortly after preparation
b Phase separation after a few days of preparation
c Phase separation after 2 weeks of preparation
permeation. Chemical stability was checked after 3 months at room temperature and no 
appreciable loss in activity under these conditions was observed. Long term stability at 
different temperatures is planned.
299–309.
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Permeation study
Ex vivo experiments. – Neonate rat epidermis (dorsal side) was used as a skin model. 
The rats used were Spraque Dawley, 2–3 days old and weighing 5–10 g. All experimental 
protocols were approved by the Animal Welfare Committee and complied with the Use of 
Laboratory Animals in the Health Sciences Center, Kuwait University.
Rats were euthanized using carbon dioxide asphyxiation before experiments and the 
epidermis was removed by a heat separation technique (27). The entire skin of neonate rats 
was soaked in water at 60 °C for 60 s, followed by careful removal of the epidermis. The 
epidermis so prepared was washed with water and examined for physical damage with a 
magnifying lens. The epidermis that was free from physical damage was used for the ex vivo 
permeation studies in vertical Franz diffusion cells (PermeGear Inc., USA). Epidermis was 
mounted between the compartments of diffusion cells, with the epidermal side facing the 
donor compartment and the subcutaneous side facing the receptor compartment. The effective 
diffusion area was 0.64 cm2 and the donor compartment volume was 1 mL while that of the 
receiver chamber was 5 mL. The diffusion cell was maintained at 32 °C. At predetermined 
time intervals, permeate samples were collected (0.3 mL) from the receptor compartment, 
diluted with methanol and assayed for T content by the HPLC method described earlier. The 
samples were replaced with an equal volume of receptor fluid maintained at 32 °C.
Several fluids were initially tested in the receptor compartment, including buffer pH 
7.2 and hydroalchoholic solutions with variable proportions of ethanol, and 50 % ethanol 
in water was used as the receptor fluid throughout the study.
In vivo permeation experiments. – Two formulations (F12 and F19) were selected for the 
in vivo study based on their good physical stability and ex vivo permeation results. Each 
preparation was applied repeatedly onto the dorsal side (7–8 cm2) of neonatal rats. The two 
formulations were applied as 5 µL every 30 min over 4 hours to allow evaporation of alco-
hol and retention on the skin without appreciable runoff. Excess material was removed 
with filter paper before skin removal. No assessment of the material remaining on the skin 
was done. Subsequently, the skin area used in the permeation study was removed and 
epidermis was separated (as described under the ex vivo permeation study) from the sub-
cutaneous layer, crushed and extracted with successive volumes of methanol, made to 10 
mL, vortexed, and finally centrifuged before HPLC analysis of T retained in each skin 
layer. Triplicate experiments were run for each product under investigation. A sample of 
the supernatant was used for HPLC determination of T content as described earlier. The 
purpose of this procedure was to assess if any T was permeated through the epidermis 
and retained in deeper skin layers. Control experiments were run on naïve animals to 
determine naturally present T.
Extraction efficiency of T was determined by successive local application of the stan-
dard solution of T in methanol (equivalent to the same concentration in the formulation) to 
each subcutaneous layer and epidermis of the neonatal rat skin, and treated in the same way 
as described above for the in vivo permeation of F12 and F19. Similarly, an individual skin 
layer was crushed, extracted with successive portions of methanol and made up to 10 mL, 
centrifuged, and the amount of T extracted in each case was determined. Further, the 
amounts of T retained in the different parts, epidermis, subcutaneous layer, and full-thick-








Gel formulations. – Table I shows the composition and viscosity of the prepared gel 
formulations. GF1, GF4 and GF5 showed phase separation, while GF2 showed droplet 
separation of oily T shortly after separation. Stable gel formulations (GF3, GF6 and GF7) 
were subjected to ex vivo permeation studies. These formulations exhibited either weak or 
no permeation even after 24 or 48 hours. This observation may be explained by the viscous 
nature of such formulations (72–279 mPa s), and by retarding the molecular diffusion and 
permeation of the large molecular mass T. The presence of some oily ingredients such as 
isopropyl myristate in some gel formulations, although it is known to have permeation 
enhancing properties (12), more likely trapped the non-polar vitamin molecules and there-
by retarded drug diffusion and permeation. Accordingly, it was decided to focus more on 
formulation of non-oily and monophasic liquid formulations with low viscosity.
Liquid formulations. – Liquid emulsion formulations of T (F1-F6) and simple solutions 
of T (F7-F11) exhibited low viscosity values (8–22 mPa s), compared to the gel formulations 
(Table II). All emulsion formulations showed relatively short-term stability compared to 
the other solution formulations, except in the case of F11which showed phase separation a 
few days after preparation (Table II). This last observation may be explained by the rela-
tively higher T concentration (9.75 %) compared to a similar one containing 7.4 % T (F10).
Liquid monophasic formulations containing TPGs. – A set of liquid formulations (F12-F21) 
containing TPGs as solubilizer/enhancer were prepared (Table II). These formulations 
showed very good physical stability and no separation was observed after 6 months under 
the study conditions described earlier. TPGs were found to have good enhancing effect on 
permeation and in one study it was concluded that TPGs and ethanol synergistically en-
hanced griseofulvin permeation and drug retention in the skin (28). Therefore, F12-F21 
formulations containing TPGs were further tested for ex vivo permeation and F12 and F19 
were selected for the in vivo permeation study. The results are discussed under »Skin Per-
meation Study« hereafter. These formulations (F12-F21) were stable without signs of phase 
separation for more than 6 months at 25 °C. No appreciable loss of T content was detected 
under the same experimental conditions.
Ex vivo permeation study
Gel formulations. – Some stable gel formulations (GF3 and GF7) did not lead to any 
permeation of T, while GF6 showed slight permeation (0.0137 %) after 24 h. This finding 
highlights the fact that although gel formulations are generally very popular and pre-
ferred by consumers, they hinder the permeation process due to their viscous nature (72-
279 mPa s), especially with a high molecular weight permeant like T.
Liquid emulsion formulations. – Formulations containing Span and Tween (F1-F6) exhib-
ited low permeation after 24 h, amounting to 0.0018 and 0.014 % of the amount of T applied 
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Monophasic liquid formulations. – Based on the observed negative effect of emulsion 
systems on physical stability and T permeation, the following solution formulations were 
investigated. Table II summarizes the composition of these formulations (F7-F21), along 
with their viscosity and %-cumulative permeation after 24 h. Inclusion of DMSO and re-
placement of water (in F1-F6) with PEG 400 (F8-F10) or propylene glycol (F7) resulted in 
better permeation. The calculated %-permeation range was 0.017–0.029 % (F8-F10) and 0.019 
% (F7). Furthermore, inclusion of TPGs improved the %-permeation, amounting to 0.05 % 
(F12) and 0.149 % (F19) after 24 h. TPGs alone did not contribute to T permeation results, as 
evidenced by the T-free formulation (F15) where no T permeation was detected. The rela-
tively higher permeation observed with TPG formulations may be explained in terms of a 
synergistic enhancing permeation of DMSO and TPGs. In addition, the synergistic effect of 
TPGs and ethanol on enhancing griseofulvin penetration was previously reported (28). 
Ethanol-free formulation (F14) showed phase separation and was therefore dropped from 
the permeation study. Further, the cumulative amounts of T permeated at each time inter-
val after starting the study were calculated according to Fick’s first law of diffusion and 
were further used to construct the permeation curves (Fig. 1), as discussed hereafter.
Kinetic analysis of ex vivo permeation data
The trans-membrane diffusion profile was determined by the analysis of the cumula-
tive amount of T in the receptor compartment after predetermined time intervals up to 24 
h. Assuming a steady state condition, the diffusion process follows Fick’s first law:
 dQ/dt = PS(CD− CR) (Eq. 1)
where PS (cm/h) is the skin permeability coefficient and CD and CR (g cm–3) are drug con-
centrations in the donor and receptor chambers, respectively, while Q is the cumulative 
amount diffused through a unit of skin surface (µg cm–2).
Fig. 1. Kinetic plots of the cumulative amount (Q, µg cm–²) of alpha-tocopherol permeated from liquid 
formulations (F12-F21) vs. time (h) following the ex vivo study.
299–309.
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Integration of Eq. (1) gives:
 Q = PS(CD− CR) t (Eq. 2)
Fig. 1 demonstrates the linear relationships between Q and time, assuming infinite 
dose conditions (CD >> CR).
The flux J (µg cm–2 h–1) calculated from the slope of Q vs. time plots during the steady 
state of the kinetic study afforded the skin permeability coefficient, Eq. (3).




The permeability coefficient and flux of different formulations were calculated and 
the values are summarized in Table IV.
The reported flux values for T in this study (0.437–2.946 µg cm–2 h–1), although rela-
tively low, are higher than those reported in a previous work, being 1.3 × 10–3 and 9.74 × 
10–3 µg cm–2 h–1 from a W/O and O/W emulsion, respectively (29). In addition, the observed 
flux values in our formulations were much higher than the reported corresponding values 
through a reconstructed human epidermis (RHE) membrane, where the reported values 
were ≈ 0 for each type of tested emulsions (29).
Further, the values of permeation coefficients observed in the present study (4.83 × 
10–6 – 3.18 × 10–5 cm h–1) were similar to those determined by Gabbanini et al. through a 
synthetic membrane (4 × 10–5 and 3 × 10–4 cm h–1 from W/O and O/W emulsions, respec-
tively) (29). Also, the permeation coefficients from the tested emulsions by the same au-
thors using the RHE membrane were found to be ≈ 0, which is lower than the values de-
termined in our investigations (4.83 × 10–6 – 3.18 × 10–5 cm h–1) (Table IV).
On the other hand, the flux and permeation coefficient values for water soluble vita-
mins reported by Gabbanini et al. for ascorbic acid and pyridoxine were by far higher than 
those reported for the investigated fat-soluble vitamins a-tocopherol and retinol acetate 
(29).
The afore-mentioned results and previous data reported from this laboratory (30) con-
firm the challenging nature of transdermal permeation of T/TA owing to their exception-
ally high lipophilic nature and large molecular mass required for optimum transdermal 
permeation.
In vivo permeation
The amount of T along with the % retained in the epidermis, subcutaneous layer, and 
full-thickness skin after repeated application of two formulations (F12 and F19) are sum-
marized in Table V. The amount retained in the full thickness skin was calculated by add-
ing that retained in the epidermis to that found in the subcutaneous layer. Corrected val-
ues of permeation data were calculated, based on the determined extraction efficiency 
from each of the epidermis, subcutaneous layer and full skin (Table IV). The results dem-
onstrate higher retention properties of the epidermal layer compared to subcutaneous 
tissues. The difference is more appreciable when we calculate the amount of T retained per 
g of skin layers, being 1377 µg g–1 and 1.13 µg g–1 for the epidermal and subcutaneous layers, 
respectively. The amounts and % of T retained by each skin layer after application of F12 
299–309.
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Table III. Permeation coefficients (Ps) and flux (J) values of alpha-tocopherol (T) from monophasic-TPG 
formulations (F12-F21) following the ex vivo study
Formulation J, slope (µg cm–2 h–1) Cd (µg cm–3) Ps (cm h–1)
F12 1.8297 90470 2.02E-05
F13 0.4374 90470 4.83E-06
F14a – – –
F15b – – –
F16 1.9749 86360 2.29E-05
F17 2.4148 82600 2.92E-05
F18 2.9461 92680 3.18E-05
F19 1.0026 47500 2.11E-05
F20 1.2837 95000 1.35E-05
F21 1.0220 95000 1.08E-05
a Complete phase separation
b Alpha-tocopherol = 0.0 %











Skin part EPa STb F. Skinc EP ST FS EP ST F. Skin EP ST F. Skin
F12
Average 259.69 22.57 282.26 1377.66 39.07 1416.73 8.92 1.13 10.04 12.71 2.14 16.33
± SD 68.13 11.58 77.78 371.74 0.58 379.60 2.41 0.58 2.93    
F19
Average 146.04 55.19 201.23 675.56 77.94 753.51 7.69 2.90 10.58 10.97 5.55 17.34




and F19 were very close, indicating that increasing T concentration from 5.0 % (F19) to 
9.5 % (F12) did not increase the amount of T permeated or its % retained. Although these 
values seem relatively low, they are nevertheless higher than the permeation results re-
ported in previous studies (22, 29). However, more investigations are necessary to further 
enhance the transdermal permeation of T for better therapeutic and cosmetic outcomes.
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CONCLUSIONS
Use of hydrophilic gel-forming polymers and emulsions for transdermal delivery of 
alpha-tocopherol was found to be inappropriate. Monophasic systems containing ethanol, 
DMF, DMSO as solvents and/or enhancers, in addition to TPGs as enhancer, were found to 
be the best formulations in this study. In vivo data demonstrated that the epidermis is the 
main site for the retention of T, and increasing T concentration did not result in better 
permeation or retention. Although the %-retention values of T in full skin seem relatively 
low (16.33–17.34 %), they are higher than the permeation results reported in previous stud-
ies. The data generated from the present work highlight the challenging nature of T for 
transdermal delivery due to its extreme hydrophobic properties and high molecular mass. 
Further research is needed in this area to achieve the desirable therapeutic and cosmetic 
objectives for topical administration of T.
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